Development and evaluation of ticlopidine HCI tablets
Loading...
Date
2006
Authors
Raj Singh, Thakur Raghu
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Ticlopidine HCI is a platelet aggregation inhibitor, which is widely used in the
treatment of platelet-dependent disorders, such as cerebral vascular disease,
ischemic heart disease and peripheral vascular disease. Ticlopidine HCI
products have been reported to be unstable which could be attributed to the
type of disintegrant used in the formulation. As such, in the development of
Ticlopidine HCI tablets using commonly used disintegrants, .namely,
croscarmellose sodium, sodium starch glycolate, crospovidone (XL and XL-10)
and cornstarch, the physical stability was evaluated under stress conditions. It
was noted that the physical properties of ticlopidine HCI tablets containing
croscarmellose sodium, sodium starch glycolate and crospovidone (XL and XL-
1 0) changed on storage but tablets containing cornstarch were stable after
storage at 40°C/75%RH for 6 months. Cornstarch was selected as disintegrant
in the preparation of ticlopidine HCI tablets. The amount and the mode of
incorporation of cornstarch (intragranular or distributed between intragranular
and extragranular phases) were varied to achieve in vitro release profile as
closely similar as possible to that of the reference product, Ticlid®. A univariate
ANOVA method and fit factors (difference factor and similarity factor) were used
for dissolution profile comparisons. The dissolution profile of formulation F6
(containing 9% cornstarch with 6% added intragranularly and 3%
extragranularly) was found to be similar to that of Ticlid®. The fit factors were
found to be more superior than the univariate ANOVA method. F6 tablets were
stable in physical and chemical properties after 6-month storage at
40°C/75%RH and the estimated shelf-life was 65.8 months, which could be
further extended by protecting the tablets in a suitable package. Prior to the in
vivo study, a simple, specific and sensitive HPLC method with UV detection was
developed and validated for the quantification of ticlopidine in rabbit plasma.
The in vivo performance of the final formulation, Formulation F6, was evaluated
by conducting bioavailability and bleeding t1me studies in comparison with
Ticlid® using twelve healthy white New Zealand female rabbits in a randomized,
two-way crossover design. The rate and extent of absorption as well as the
bleeding time of Formulation F6 were fo~nd to be comparable with Ticlid®. In
addition, the time required to achieve the maximum bleeding time corresponded
to that of T max values for both preparations. In conclusion, a stable generic
ticlopidine HCI tablet preparation containing cornstarch as disintegrant
demonstrating similar in vitro dissolution profile and in vivo performance as that
of Ticlid® was successfully developed.
Description
Keywords
Ticlopidine HCI tablets